UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · IEX Real-Time Price · USD
15.14
-1.34 (-8.13%)
At close: Jul 2, 2024, 4:00 PM
15.17
+0.03 (0.20%)
After-hours: Jul 2, 2024, 7:16 PM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $84.30M in the twelve months ending March 31, 2024, with 24.00% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $18.78M with 9.24% year-over-year growth. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.
Revenue (ttm)
$84.30M
Revenue Growth
+24.00%
P/S Ratio
7.39
Revenue / Employee
$413,245
Employees
204
Market Cap
622.71M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
Dec 31, 2016 | 17.53M | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.13B |
PetIQ | 1.12B |
Phibro Animal Health | 999.56M |
InnovAge Holding | 741.33M |
The Pennant Group | 575.34M |
Evolus | 219.70M |
OrthoPediatrics | 161.83M |
Sage Therapeutics | 91.06M |
URGN News
- 15 days ago - UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - Business Wire
- 15 days ago - UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 19 days ago - Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions - Business Wire
- 19 days ago - AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100 - Business Wire
- 19 days ago - UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
- 25 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 - Business Wire
- 27 days ago - UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference - Business Wire